Key segments covered in this report are: By drugs type Bisphosphonates Parathyroid Hormone Therapy Drugs Calcitonin Selective Estrogen Receptors Modulators (SERMs) RANK Ligand
InhibitorsKey geographies evaluated in this report are: North America U.
Denosumab is the world s first fully human monoclonal antibody to target RANK Ligand
, an essential mediator of osteoclast formation.
XGEVA is the first and only RANK Ligand
inhibitor approved by the FDA indicated for the prevention of skeletal-related events (SREs) in patients with bone metastases from solid tumors.
Denosumab, a RANK ligand
inhibitor, was first approved in June 2010 for treating postmenopausal women with osteoporosis at high risk of fracture and is marketed as Prolia.
By targeting RANK Ligand
, Prolia offers an innovative new approach that helps reduce fracture risk.
Further studies identified the RANK ligand
pathway as the key cell-signalling pathway responsible for the indirect control of breast stem cells in pregnancy.
Denosumab is the first fully human monoclonal antibody in late stage clinical development that specifically targets RANK Ligand
, an essential regulator of osteoclasts (the cells that break down bone).
Denosumab, a genetically engineered antibody, is designed to block the action of a protein called RANK Ligand
, which activates signals that lead to the breakdown of bones.
The antibody, which is believed to suppress bone resorption by binding to RANK ligand
on osteoclasts, appeared to have a very rapid onset of effect, said Dr.
The relative ratio of OPG and RANK ligand
in the bone marrow microenvironment may determine the number of active osteoclasts, bone resorption rate, and bone mass.
Enhanced RANK ligand
expression and responsivity of bone marrow cells in Paget's disease of bone.
Increased bone resorption in SF mice was suggested by a trend towards increased mRNA expression of the pro-resorptive cytokine RANK ligand
and significantly elevated serum TRAP levels.